Prescient Therapeutics Limited (ASX:PTX)
Australia
· Delayed Price · Currency is AUD 0.0460
-0.0010 (-2.13%)
Apr 30, 2025, 4:10 PM AEST
Prescient Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Other Revenue | 3.02 | 3.71 | 2.43 | 1.89 | 1.19 | 1.03 | Upgrade
|
| Revenue | 3.02 | 3.71 | 2.43 | 1.89 | 1.19 | 1.03 | Upgrade
|
| Revenue Growth (YoY) | -2.96% | 52.89% | 28.52% | 59.37% | 15.17% | -37.53% | Upgrade
|
| Gross Profit | 3.02 | 3.71 | 2.43 | 1.89 | 1.19 | 1.03 | Upgrade
|
| Selling, General & Admin | 4.1 | 3.71 | 3.2 | 2.82 | 2.29 | 1.55 | Upgrade
|
| Research & Development | 4.63 | 6.97 | 6.22 | 3.4 | 2.49 | 2.76 | Upgrade
|
| Operating Expenses | 8.83 | 10.9 | 9.89 | 7.1 | 5.43 | 4.49 | Upgrade
|
| Operating Income | -5.81 | -7.19 | -7.46 | -5.21 | -4.24 | -3.46 | Upgrade
|
| Interest Expense | -0.01 | - | - | -0.01 | -0.01 | -0 | Upgrade
|
| Interest & Investment Income | 0.51 | 0.69 | 0.46 | 0.04 | 0.07 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.03 | -0.02 | -0.01 | 0.06 | -0.01 | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -5.35 | -6.52 | -7 | -5.12 | -4.2 | -3.37 | Upgrade
|
| Asset Writedown | -1.72 | -1.72 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.05 | 0.05 | Upgrade
|
| Pretax Income | -7.07 | -8.24 | -7 | -5.12 | -4.15 | -3.32 | Upgrade
|
| Net Income | -7.07 | -8.24 | -7 | -5.12 | -4.15 | -3.32 | Upgrade
|
| Net Income to Common | -7.07 | -8.24 | -7 | -5.12 | -4.15 | -3.32 | Upgrade
|
| Shares Outstanding (Basic) | 805 | 805 | 728 | 648 | 612 | 394 | Upgrade
|
| Shares Outstanding (Diluted) | 805 | 805 | 728 | 648 | 612 | 394 | Upgrade
|
| Shares Change (YoY) | 2.10% | 10.69% | 12.31% | 5.88% | 55.18% | 61.22% | Upgrade
|
| EPS (Basic) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Free Cash Flow | -9.7 | -7.4 | -6.19 | -4.32 | -3.97 | -2.32 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -192.44% | -193.58% | -307.14% | -275.75% | -357.80% | -336.62% | Upgrade
|
| Profit Margin | -233.95% | -221.91% | -288.47% | -270.85% | -349.97% | -322.65% | Upgrade
|
| Free Cash Flow Margin | -321.17% | -199.28% | -254.97% | -228.50% | -335.08% | -225.11% | Upgrade
|
| EBITDA | -5.81 | -7.19 | -7.46 | -5.21 | -4.24 | -3.46 | Upgrade
|
| EBITDA Margin | -192.43% | -193.56% | - | -275.68% | - | - | Upgrade
|
| D&A For EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| EBIT | -5.81 | -7.19 | -7.46 | -5.21 | -4.24 | -3.46 | Upgrade
|
| EBIT Margin | -192.44% | -193.58% | - | -275.75% | - | - | Upgrade
|
Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.